Company / Free Cash Flow
Seres Therapeutics, Inc. Free Cash Flow History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$125.3M
FY2025
5-year range
-$125.3M / -$2.9M
FY2021-FY2025
Trend
-4254.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow changed -4255% YoY in FY2025, a notable deviation from the 9-year average annual change of -544%.
Based on SEC 10-K filings.
-$125M in FY2025.
Declined from -$94M to -$125M over the past 3 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 4254.7% year-over-year.
- Peak free cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$125.3M | -4254.7% |
| FY2023 | -$2.9M | +96.9% |
| FY2022 | -$94.2M | -21.5% |
| FY2021 | -$77.5M | -19.6% |
| FY2020 | -$64.8M | +19.2% |
| FY2019 | -$80.2M | -457.6% |
| FY2018 | $22.4M | +149.6% |
| FY2017 | -$45.2M | -298.0% |
| FY2016 | -$11.4M | -106.7% |
| FY2015 | -$5.5M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026